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We describe the association of familial multiple subcutaneous lipomatosis with a PALB2 gene
mutation (c.2716delT) and its increased predilection to cancers.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Familial multiple subcutaneous lipomatosis (FML) is a rare
disorder with autosomal dominant inheritance. Specific
genetic mutations associated with this disease have not
been described. Its association with increased predilection
to cancers is a rarer entity. We describe a case of FML
and its association with a PALB2 mutation and increased risk
of cancer.Case report
A 41-year-old man who had multiple subcutaneous lipo-
matosis (Figure 1) presented with a right axillary lymph
nodal mass ongoing for 2 years. Clinical examination
revealed enlarged right axillary nodes with multiple sym-
metric subcutaneous lipomas all over the body sparing the
neck and shoulders. Excision biopsy of the right axillary
lymph node was suggestive of infiltrating ductal carcinoma
(estrogen receptor negative, progesterone receptor nega-
tive, and HER2neu negative, ki67 40%). Staging workup did
not reveal any distant metastasis. He was diagnosed as tri-
ple negative male breast cancer, Stage II. He was treated
with four cycles of neoadjuvant chemotherapy consisting
of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/
m2. After neoadjuvant chemotherapy he underwent
Figure 1 Index case showing multiple lipomatosis in the upper limbs (arrows).
Familial Multiple Subcutaneous Lipomatosis 155modified radical mastectomy. He completed adjuvant
chemotherapy with weekly paclitaxel 80 mg/m2 and is pre-
sently on follow up.
Multiple lipomatosis was present in his father, three
elder siblings (1 deceased sister), and his son, but not in
his younger brother (Figure 2). His deceased elder sister
had succumbed to uterine cancer which was diagnosed at
the age of 46 years. Genetic testing revealed a novel dele-
tion in the PALB2 gene (c.2716delT) in proband, elder sib-
lings, and son (Figure 2). His younger sibling who did not
have a clinical manifestation of lipomatosis was negative
for this PALB2 gene mutation (Figure 3). The status of the
PALB2 mutation is not known for the father and elder sister
who died of uterine cancer.Figure 2 Pedigree of the family with PALB2 mutation. Age at
deceased.Discussion
FML, also known as Dercum disease, is an autosomal domi-
nant disease [1]. FML is characterized by multiple symmet-
rically distributed lipomas all over the body sparing the neck
and shoulders. A specific gene mutation for FML has not
been identified yet [2]. Ga´mez et al. [3] have described
an association with mutations in mitochondrial DNA.
PALB2 (partner and localizer of BRCA2) is an intranuclear
protein, which by its interaction with BRCA2 helps in
anchoring BRCA2 to nuclear structures [4]. BRCA2 is
involved in the repair of DNA by homologous recombination
of double strand DNA breaks. Familial breast and ovariandiagnosis of cancer for II/3 and II/6. Slashed symbols denote
Figure 3 Sanger sequencing data (electropherogram) from the individual showing heterozygous deletion of nucleotide ‘T’ at
position c.2716 in the PALB2 gene. PALB2 genetic alteration: c.2716delT, chr16:23637589delA, p.Trp906GlyfsTer17.
156 N. Reddy et al.cancer syndromes are strongly associated with germ line
mutations of BRCA1 and BRCA2 genes [5]. BRCA negative
familial breast cancer has been implicated with many genes
including PALB2. A monoallelic mutation in PALB2 has been
associated with a two-fold increased risk of breast cancer
[6]. Biallelic mutations of PALB2 has been associated with
a subset of Fanconi anemia [7]. PALB2 mutations have also
been reported to be associated with pancreatic cancer [8]
and ovarian cancers [9].
Many mutations have been reported in the PALB2 gene
but to our knowledge c.2716delT has not yet been reported.
In the present family, members who had lipomatosis were
positive for this novel PALB2 gene mutation but not the
younger sibling (II/1). This probably suggests that this novel
PALB2 mutation may be associated with familial
lipomatosis.
PALB2 genetic mutation is a known risk factor for breast
cancer. FML may be related to a novel PALB2 genetic muta-
tion c.2716delT with associated increased risk of predilec-
tion to cancer.
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